Primary fibroblasts isolated from histologically normal tissue adjacent to the tumor, cryopreserved at early passage. The donor-matched normal control for CAFs from the same patient. Research use only.
$1,000
| Tumor type | Non-Small Cell Lung Cancer (adenocarcinoma, squamous cell carcinoma) |
| Species | Human |
| Tissue source | Tumor-adjacent normal tissue |
| Max recommended passages / lifespan | TBD – finite lifespan, not immortalized |
| Post-thaw viability (guaranteed min %) | ≥ 50% (website: 'viability data (50%+ post-thaw)'). Low for a paid vial – what will DRL guarantee? |
| Cells per vial | Website says ≥ 1 × 10^5 cells, 'flow-sorted cell fraction' – looks copied from the TIL entry. Confirm. |
| Freezing medium | TBD – website names CryoStor for organoids; same for cells? |
| Recommended culture medium | TBD |
| Medium kit available? | TBD |
| Storage on arrival | Liquid nitrogen, vapor phase (website) |
| Ships as | Frozen, on dry ice (website) |
| Biosafety level | BSL-2 (website) |
| Donor data provided | Website: 'comprehensive clinical reports', 'clinical metadata intact'. Which fields exactly? |
| Marker panel | TBD – which markers show 'normal' vs activated state? |
| Mycoplasma test | Included – 'mycoplasma-free' (website) |
| Certificate of Analysis (CoA) | Included – template needed |
| Intended use | Research Use Only. Not for use in humans or for diagnostic procedures. |
| Consent covers commercial sale of derived cells? | TBD (website says 'IRB-approved' – consent scope still unknown) |
